HAUPTMENÜ
AWARDS
Forschergeist gefragt: 14. Novartis Oppenheim-Förderpreis für MS-Forschung ausgelobt
FernstudiumCheck Award: Deutschlands beliebteste Fernhochschule bleibt die SRH Fernhochschule
Vergabe der Wissenschaftspreise der Deutschen Hochdruckliga und der Deutschen Hypertoniestiftung
Den Patientenwillen auf der Intensivstation im Blick: Dr. Anna-Henrikje Seidlein…
Wissenschaft mit Auszeichnung: Herausragende Nachwuchsforscher auf der Jahrestagung der Deutschen…
VERANSTALTUNGEN
Wichtigster Kongress für Lungen- und Beatmungsmedizin ist erfolgreich gestartet
Virtuelle DGHO-Frühjahrstagungsreihe am 22.03. / 29.03. / 26.04.2023: Herausforderungen in…
Pneumologie-Kongress vom 29. März bis 1. April im Congress Center…
Die Hot Topics der Hirnforschung auf dem DGKN-Kongress für Klinische…
Deutscher Schmerz- und Palliativtag 2023 startet am 14.3.
DOC-CHECK LOGIN
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018
- EMA’s human medicines committee (CHMP) recommended four medicines for approval, including a medicine for use in countries outside the European Union, at its November 2018 meeting.
London, UK (November 16, 2018) – The CHMP adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the treatment of human African trypanosomiasis, commonly known as sleeping sickness, due to Trypanosoma brucei gambiense. This is the tenth medicine recommended by EMA under Article 58, a mechanism that allows the CHMP to assess and give opinions on medicines for use outside the European Union. For more information, please see the press release in the grid below.
Erleada (apalutamide) received a positive opinion for the treatment of non-metastatic castration resistant prostate cancer.
The CHMP recommended granting a marketing authorisation for Macimorelin Aeterna Zentaris (macimorelin), for the diagnosis of growth hormone deficiency in adults.
The generic medicine Silodosin Recordati (silodosin) received a positive opinion from the CHMP for the treatment of the signs and symptoms of benign prostatic hyperplasia.
Four recommendations on extensions of therapeutic indication
The Committee recommended extensions of indication for Kisqali, Mabthera, Orkambi and Ravicti.
Positive recommendations on extension of therapeutic indication following re-examination
The Committee recommended an extension of therapeutic indication for Blincyto (blinatumomab) in patients with residual cancer cells in the body after previous treatment, after re-examining its negative opinion for this medicine adopted in July 2018.
The CHMP also adopted a positive opinion for the use of Opdivo (nivolumab) and Yervoy (ipilimumab) in combination to treat renal cell carcinoma (kidney cancer), after re-examining its negative opinion adopted in July 2018.
For more information on these positive opinions following re-examination please see the question-and-answer documents in the grid below.
Outcome of review on quinolone and fluoroquinolone antibiotics
The CHMP recommended suspending some quinolone and fluoroquinolone antibiotics and introducing changes including restrictions on the use of all others following a review of disabling and potentially permanent side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on these medicines in June 2018. For more information, please see the public health recommendation in the grid below.
Withdrawal of extension of indication application
The application to extend the use of Tecentriq (atezolizumab) to treat kidney cancer was withdrawn. A question-and-answer document on this withdrawal is available in the grid below.
Agenda and minutes
The agenda of the November 2018 meeting is published on EMA’s website. Minutes of the October 2018 CHMP meeting will be published in the coming weeks.
CHMP statistics
Key figures from the November 2018 CHMP meeting are represented in the graphic below.
Positive recommendations on new medicines
Name of medicine | Erleada |
INN | apalutamide |
Marketing-authorisation applicant | Janssen-Cilag International N.V. |
Therapeutic indication | Treatment of non-metastatic castration resistant prostate cancer |
Name of medicine | Macimorelin Aeterna Zentaris |
INN | macimorelin |
Marketing-authorisation applicant | Aeterna Zentaris GmbH |
Therapeutic indication | Diagnosis of growth hormone deficiency in adults |
CHMP summary of positive opinion for Macimorelin Aeterna Zentaris (PDF/62.48 KB)
First published: 16/11/2018
EMA/CHMP/777751/2018
Positive recommendation on new generic medicine
Name of medicine | Silodosin Recordati |
INN | silodosin |
Marketing-authorisation applicant | Recordati Ireland Ltd |
Therapeutic indication | Treatment of the signs and symptoms of benign prostatic hyperplasia |
CHMP summary of positive opinion for Silodosin Recordati (PDF/73.33 KB)
First published: 16/11/2018
EMA/766073/2018
Positive recommendation on medicine for use outside the European Union
Name of medicine | Fexinidazole Winthrop |
INN | fexinidazole |
Opinion holder | sanofi-aventis groupe |
Therapeutic indication | Treatment of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense |
More information | Press release: CHMP recommends first oral-only treatment for sleeping sickness |
CHMP summary of opinion for Fexinidazole Winthrop (PDF/73.53 KB)
First published: 16/11/2018
EMA/791484/2018
Positive recommendations on extensions of indications
Name of medicine | Kisqali |
INN | ribociclib |
Marketing-authorisation applicant | Novartis Europharm Limited |
CHMP post-authorisation summary of positive opinion for Kisqali (II-04) (PDF/64.74 KB)
First published: 16/11/2018
EMA/CHMP/795769/2018
Name of medicine | Mabthera |
INN | rituximab |
Marketing-authorisation applicant | Roche Registration GmbH |
CHMP post-authorisation summary of positive opinion for MabThera (II-149) (PDF/71.67 KB)
First published: 16/11/2018
EMA/CHMP/790642/2018
Name of medicine | Orkambi |
INN | lumacaftor / ivacaftor |
Marketing-authorisation applicant | Vertex Pharmaceuticals (Europe) Ltd |
CHMP post-authorisation summary of positive opinion for Orkambi (X-34-G) (PDF/67.93 KB)
First published: 16/11/2018
EMA/774653/2018
Name of medicine | Ravicti |
INN | glycerol phenylbutyrate |
Marketing-authorisation applicant | Horizon Pharma Ireland Limited |
Positive recommendations on extensions of indications following re-examination
Name of medicine | Blincyto |
INN | blinatumomab |
Marketing-authorisation applicant | Amgen Europe B.V. |
CHMP post-authorisation summary of positive opinion for Blincyto (II-0011) (PDF/69.16 KB)
First published: 16/11/2018
EMA/CHMP/799482/2018
First published: 16/11/2018
EMA/800602/2018
Name of medicine | Opdivo |
INN | nivolumab |
Marketing-authorisation applicant | Bristol-Myers Squibb Pharma EEIG |
CHMP post-authorisation summary of positive opinion for Opdivo (WS-1278) (PDF/72.85 KB)
First published: 16/11/2018
EMA/CHMP/788598/2018
Name of medicine | Yervoy |
INN | ipilimumab |
Marketing-authorisation applicant | Bristol-Myers Squibb Pharma EEIG |
CHMP post-authorisation summary of positive opinion for Yervoy (WS-1278) (PDF/71.11 KB)
First published: 16/11/2018
EMA/795695/2018
Public-health recommendation
Name of medicine | Quinolone- and fluoroquinolone-containing medicinal products |
INN | nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin |
First published: 16/11/2018
EMA/795349/2018
Outcomes of arbitration procedures
Name of medicine | Diclofenac sodium spray gel 4% |
INN | diclofenac |
First published: 16/11/2018
EMA/631720/2018
Name of medicine | Diotop capsules |
INN | diclofenac / omeprazole |
First published: 16/11/2018
EMA/790726/2018
Withdrawal of extension of indication application
Name of medicine | Tecentriq |
INN | atezolizumab |
Marketing-authorisation applicant | Roche Registration GmbH |
First published: 16/11/2018
EMA/798527/2018
Other updates
Start of community reviews – CHMP meeting of 12-15 November 2018 (PDF/66.92 KB)
First published: 16/11/2018
EMA/712987/2018
First published: 16/11/2018
EMA/CHMP/SAWP/800757/2018
Related content
Macimorelin Aeterna Zentaris: Pending EC decision
Tecentriq: Withdrawn application
Silodosin Recordati: Pending EC decision
Yervoy: Paediatric investigation plan
Yervoy: Paediatric investigation plan
MabThera: Paediatric investigation plan
MabThera: Paediatric investigation plan
Blincyto: Paediatric investigation plan
Opdivo: Paediatric investigation plan
Opdivo: Paediatric investigation plan
Orkambi: Paediatric investigation plan
Diclofenac Sodium Spray Gel 4%: Article 29(4) referrals
Diotop capsules: Article 29(4) referrals
Quinolone- and fluoroquinolone-containing medicinal products: Article 31 referrals
Medicines for use outside the EU
Fexinidazole Winthrop H-W-2320
Related content
CHMP recommends first oral-only treatment for sleeping sickness
Committee for Medicinal Products for Human Use (CHMP): 12-15 November 2018
CHMP: Agendas, minutes and highlights
Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.
European Medicines Agency, 16.11.2018 (tB).